Completed OBSERVATIONAL NCT00834353

Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis

Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis

Sponsor: Maulana Azad Medical College

Conditions Pulmonary Tuberculosis

Interventions ATT

Updated 5 times since 2017 Last updated: Feb 2, 2009 Started: Sep 30, 2005 Primary completion: Mar 31, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00834353, this observational or N/A phase trial focuses on Pulmonary Tuberculosis and remains completed. Sponsored by Maulana Azad Medical College, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maulana Azad Medical College

Data source: Maulana Azad Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Delhi, India